Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

N. Lawrence, A. Martin, G. Toner, M. Stockler, L. Buizen, D. Thomson, V. Gebski, M. Friedlander, A. Yeung, N. Wong, H. Gurney, M. Rosenthal, N. Singhal, G. Kichenadasse, S. Wong, C. Lewis, P. Vasey, P. Grimison

    Research output: Contribution to journalLetter

    1 Citation (Scopus)

    Abstract

    Germ cell tumours such as testicular cancer typically affect adolescent and young adult males. Since the introduction of cisplatin, outcomes for patients with advanced germ cell tumours have improved with cure rates exceeding 80% overall. However, outcomes are considerably worse for patients with intermediate or poor prognostic features with cure rates of only 79% and 48%, respectively.
    Original languageEnglish
    Pages (from-to)2302-2303
    Number of pages2
    JournalAnnals of Oncology : Official Journal of the European Society for Medical Oncology
    Volume27
    Issue number12
    DOIs
    Publication statusPublished - 1 Dec 2016

    Fingerprint Dive into the research topics of 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)'. Together they form a unique fingerprint.

  • Cite this